The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) hit a new 52-week low and has $12.08 target or 14.00% below today’s $14.05 share price. The 8 months bearish chart indicates high risk for the $430.09 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $12.08 price target is reached, the company will be worth $60.21M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 110,079 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 28.53% since March 31, 2016 and is downtrending. It has underperformed by 31.06% the S&P500.
Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on November, 3. They expect $-0.69 earnings per share, down 60.47% or $0.26 from last year’s $-0.43 per share. After $-0.66 actual earnings per share reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm has “Outperform” rating given on Friday, October 9 by William Blair. On Friday, August 19 the stock rating was maintained by Citigroup with “Sell”. The firm has “Mkt Perform” rating by JMP Securities given on Friday, September 25. Citigroup downgraded the shares of ATRA in a report on Tuesday, December 15 to “Sell” rating. The stock has “Sell” rating given by Citigroup on Monday, August 22. The stock has “Sell” rating given by Goldman Sachs on Thursday, September 15. JMP Securities maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) on Tuesday, December 15 with “Market Outperform” rating. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, November 18 report. Canaccord Genuity initiated the shares of ATRA in a report on Wednesday, September 9 with “Buy” rating.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 3.36 in 2016 Q2. Its up 2.20, from 1.16 in 2016Q1. The ratio improved, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
The Ontario – Canada-based Manufacturers Life The has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Moreover, Vanguard Group Incorporated Inc has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 679,690 shares. The New York-based Perceptive has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Ladenburg Thalmann Finance, a Florida-based fund reported 22 shares. Price T Rowe Assocs Incorporated Md has 26,753 shares for 0% of their US portfolio. Deutsche Bank & Trust Ag has 0% invested in the company for 9,779 shares. Swiss Retail Bank reported 26,100 shares or 0% of all its holdings. Metropolitan Life Ins Ny accumulated 17,716 shares or 0% of the stock. Tiverton Asset Lc last reported 0.28% of its portfolio in the stock. Moreover, Northern Tru Corporation has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 240,735 shares. Dekabank Deutsche Girozentrale has 16,200 shares for 0% of their US portfolio. Credit Suisse Ag, a Switzerland-based fund reported 20,566 shares. Neuberger Berman Grp Limited Liability last reported 629,120 shares in the company. Royal Retail Bank Of Canada has 0% invested in the company for 773 shares. The New Jersey-based Blackrock Inv Mgmt Limited Co has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA).
Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 17 insider sales for $2.07 million net activity. Ciechanover Isaac E. sold $250,446 worth of stock or 12,000 shares. Another trade for 5,395 shares valued at $85,079 was made by MCGRATH JOHN on Monday, May 16. Clark Mitchall G. sold $62,918 worth of stock. $86,344 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Soffer Gad on Monday, May 16. 1,346 Atara Biotherapeutics Inc (NASDAQ:ATRA) shares with value of $30,041 were sold by Haqq Christopher. Another trade for 1,184 shares valued at $18,897 was made by Gallagher Carol Giltner on Monday, May 16.
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Marketwatch.com which released: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Also Fool.com published the news titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.